Navigation Links
Clinical practitioners not adhering to evidence-based guidelines for osteoarthritis
Date:1/4/2011

New research found clinicians who care for patients with osteoarthritis (OA) are likely not following standard care guidelines that are based on current medical evidence. Researchers noted physicians were prescribing medications for pain and inflammation, or opting for surgical interventions rather than recommending weight loss plans or exercise programs to OA patients. Details of the this study are available in the January 2011 issue of Arthritis Care & Research, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology.

A 2002 report by the World Health Organization (WHO) estimated OA to be the fourth leading cause of years lost due to disease (YLD) worldwide. OA disability is quickly becoming a major public health concern with experts suggesting that by 2020 the number of people with OA will have doubled due to growing obesity prevalence and the aging of the "baby boomer" generation. According to the Centers for Disease Control and Prevention (CDC), arthritis and other rheumatic conditions cost the U.S. $128 billion in 2003a 24% increase since 1997. Much of the cost burden in arthritis care can be attributed to OA which accounts for a large volume of surgical procedures including total joint replacements.

Dr. David Hunter from the University of Sydney in Australia and New England Baptist Hospital in Boston, Massachusetts and colleagues reviewed how standard clinical practice diverges from evidence-based recommendations in the management of OA. "We present a potential roadmap for optimizing the quality of OA healthcare for those developing and enforcing policy decisions, and for clinicians on the frontlines of OA management to enact practice change," commented Dr. Hunter.

Current clinical practice does not reflect recommendations based upon medical evidence. The authors report that therapeutic interventions are primarily aimed at reducing pain and improving joint function by using therapies t
'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Clinical decision support systems help control inappropriate medical imaging, study suggests
2. Peptide delivers 1-2 punch to breast cancer in pre-clinical study
3. Collaboration offers NIH Clinical Center resources to Damon Runyon clinical investigators
4. Use the right metaphor to get patients to enroll in clinical trials
5. Clinical trial for Rett syndrome launched
6. Drugs are safe, active in patients normally ineligible for clinical trial
7. Swiss agency approves clinical trial of UCI-created neural stem cell therapy
8. Onconova to present clinical trials update on ON 01910.Na at American Society of Hematology Meeting
9. International clinical trial tests targeted drug for melanoma
10. Prostate cancer clinical stage does not predict recurrence
11. Growth factor regenerates tooth supporting structures: Results of a large randomized clinical trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Spring is the perfect time to ... filled with whole foods to weather perfect for outdoor ... season the nutrition experts at Brilliant Nutrition highlight five ... , 1. Eating Locally, With the abundance of fresh ... and explore, spring is a great time to take ...
(Date:5/21/2013)... Feed additives have now become an ... chain. Most of the feed additives are used in ... and powders. There are variety of feed additives available ... upon the type of animal and feed. Nutritional feed ... essential nutrition to the animal in order to gain ...
(Date:5/21/2013)... Daily Gossip Magazine published well-documented articles that are ... people informed on the latest weight loss methods by publishing ... in-depth review of Kyle Leon’s Customized Fat ... want to lose weight or stay in shape with the ... was created by a popular fitness trainer, Kyle Leon, who ...
(Date:5/21/2013)... DISCcert has served the training industry for ... DISC applications at the July 25 & 26th ... July 25 & 26th DISC certification in San Diego, ... DISC. The time-tested, proven support materials will include valuable ... training materials ; worksheets, handouts, learning activities, power-points ...
(Date:5/21/2013)... 2013) Prostaglandin analogues (PGAs), drugs which lower intraocular ... people with glaucoma, but their use is not without ... dryness, changes in eye color and other side effects. ... also cause upper and lower eyelid drooping and other ... described in PLOS ONE . , Researchers from ...
Breaking Medicine News(10 mins):Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 2Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 3Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 3Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 4Health News:Customized Fat Loss Plan Review and Diet Secrets Revealed By Daily Gossip Magazine 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Glaucoma drug can cause droopy eyelids 2
... Inc. (Nasdaq: MSON ), a developer of ... is used for the ablation of tumors and worldwide ... has purchased three patents associated with High Intensity Focused ... relate to HIFU transducer arrays method of fabrication, ultrasonic ...
... with rheumatic diseases want more information and better communication ... their conditions, according to the results of a new ... of the European League Against Rheumatism in Copenhagen, Denmark. ... understand the importance of addressing sexual health with their ...
... Friday 12 June 2009: After five years of receiving ... spondylitis (AS) showed substantial clinical benefit (ASAS40, ASsessment in ... at five years, 78.4% of AS patients had no ... junction between tendon and bone). Over this period, patients ...
... CHICAGO, June 12 Germany ... by the eastern federal states.,This is in large part ... despite the economic crisis. American investor interest in,Germany remains ... Nordex AG shared their success stories at the "How,Far ...
... , Travelers Turn to InsureMyTrip.com for Coverage Protection and ... Stating ,the scientific criteria for an influenza pandemic have ... declared the A(H1N1) virus, commonly referred to as Swine ... http://www.newscom.com/cgi-bin/prnh/20070529/NETU076LOGO ) , , "Particularly ...
... 12 June 2009: 92.8% of patients with systemic lupus ... both their physical and emotional quality of life (QoL), ... today at EULAR 2009, the Annual Congress of the ... analysis revealed that depression was the most significant factor ...
Cached Medicine News:Health News:Misonix Announces the Purchase of Patents From ProRhythm, Inc. 2Health News:Misonix Announces the Purchase of Patents From ProRhythm, Inc. 3Health News:Better access to info and dialogue with HCPs on sexual issues for rheumatology patients 2Health News:Better access to info and dialogue with HCPs on sexual issues for rheumatology patients 3Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 2Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 3Health News:American Investors Highlight Successes in Eastern Germany 2Health News:World Health Organization Declares A(H1N1) Pandemic 2Health News:World Health Organization Declares A(H1N1) Pandemic 3Health News:Anxiety and depression lower quality of life in majority of systemic lupus erythematosus patients 2
(Date:5/21/2013)... 21, 2013  BioRestorative Therapies, Inc. ("BRT" or the ... on developing stem cell based therapies for various personal ... its President and CEO, will be presenting at the ... be held on Thursday, May 30, 2013 at the ... in New York City.  Mr. Weinreb,s presentation will take ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, ... secondary analysis of its double-blind, randomized, controlled Phase ... a gene therapy product designed to deliver the ... analysis identified a more robust response to CERE-120 ... to treatment relative to those diagnosed 10 years ...
(Date:5/21/2013)... MONROVIA, Calif. , May 21, 2013 ... leading developer, manufacturer and marketer of minimally invasive ophthalmic ... upcoming investor conferences to review the Company,s recent financial ... STAAR Surgical will present at the 38 ... Boston at the Westin Waterfront ...
Breaking Medicine Technology:BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5STAAR Surgical To Present At Upcoming Investor Conferences 2
... COLLEGEVILLE, Pa., and TARRYTOWN, N.Y., May 22 ... ), and Progenics,Pharmaceuticals, Inc. (Nasdaq: PGNX ), ... with investigational oral and,intravenous formulations of RELISTOR(TM) (methylnaltrexone ... phase 2 trial, evaluated the effects of,an oral ...
... LAS VEGAS, May 22 CardioVascular,BioTherapeutics, Inc. (OTC Bulletin ... Christopher Moore to be the sponsor and general,partner of ... of,$1 million and up to $10 million of the ... am extremely impressed with CVBT,s wound healing drug, which ...
Cached Medicine Technology:Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 2Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 3Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 4Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 5Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 6Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 7Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 2Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 3
... Adjustable Post-Operative Pin Knee Brace (POP) for ... associated with ACL, PCL, MCL, and LCL ... extension in 7 increments. Can be locked ... increases compliance. Breakaway hinge bar converts long ...
... The Aircast Patellar Brace is a ... unique "horseshoe" shaped aircell stabilizes the patella ... maintain the position of the patella. During ... helping to reduce swelling and pain. A ...
... Pediatric Knee/Elbow Cryo/Cuff is specifically designed to treat ... the therapeutic benefits of controlled compression to minimize ... Due to the unique design of the cuff, ... knee and elbow of the patient. The Pediatric ...
... therapeutic benefits of controlled compression to minimize hemarthrosis ... cuff is anatomically designed to completely fit the ... available in three sizes for adults and is ... children 1 - 7 years of age. A ...
Medicine Products: